Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06545344
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-22
Brief Title:
Palliative Care Consultation to Improve Communication for Patients Considering Surgery for a Pancreatic Neoplasm
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Preoperative Specialty Palliative Care for Patients Considering Pancreatic Surgery Pilot Feasibility and Acceptability Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial evaluates a palliative care consultation for improving communication between providers and patients considering surgery for a pancreatic neoplasm Pancreatic operations have known complications that can affect quality of life Palliative care has been shown to improve patient reported quality of life and functional outcomes Receiving a palliative care consultation may improve communication and decision making for patients considering surgery for a pancreatic neoplasm
Detailed Description:
OUTLINE Patients are randomized to 1 of 2 arms
ARM I Patients receive usual care and undergo evaluation by a tumor board within 14 days of baseline
ARM II Patients attend a palliative care visit over 60 minutes to discuss their illness quality of life fears and concerns and communication preferences within 7 days of baseline Patients also undergo evaluation by a tumor board within 14 days of baseline
After completion of study intervention patients are followed up 7 days after the tumor board visit and 90 days after initiation of treatment
ARM I Patients receive usual care and undergo evaluation by a tumor board within 14 days of baseline
ARM II Patients attend a palliative care visit over 60 minutes to discuss their illness quality of life fears and concerns and communication preferences within 7 days of baseline Patients also undergo evaluation by a tumor board within 14 days of baseline
After completion of study intervention patients are followed up 7 days after the tumor board visit and 90 days after initiation of treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None